EP0003089B1 - Séchoir pour feuilles imprimées par sérigraphie - Google Patents

Séchoir pour feuilles imprimées par sérigraphie Download PDF

Info

Publication number
EP0003089B1
EP0003089B1 EP19780400265 EP78400265A EP0003089B1 EP 0003089 B1 EP0003089 B1 EP 0003089B1 EP 19780400265 EP19780400265 EP 19780400265 EP 78400265 A EP78400265 A EP 78400265A EP 0003089 B1 EP0003089 B1 EP 0003089B1
Authority
EP
European Patent Office
Prior art keywords
hurdle
conveyor
sheet
clips
bent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP19780400265
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0003089A1 (fr
Inventor
Bernard David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silium Francaise A Responsabilite Ltee Ste
Original Assignee
Silium Francaise A Responsabilite Ltee Ste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0003089(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silium Francaise A Responsabilite Ltee Ste filed Critical Silium Francaise A Responsabilite Ltee Ste
Publication of EP0003089A1 publication Critical patent/EP0003089A1/fr
Application granted granted Critical
Publication of EP0003089B1 publication Critical patent/EP0003089B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
    • B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
    • B41F23/044—Drying sheets, e.g. between two printing stations
    • B41F23/0443—Drying sheets, e.g. between two printing stations after printing
    • B41F23/0446—Wicket conveyors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
    • F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
    • F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
    • F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor

Definitions

  • the present invention relates to a dryer for sheets printed by screen printing.
  • the drying of the sheets printed by screen printing is done at present, either manually by stacking on each other drying racks on each of which is placed a sheet, or mechanically by means of dryers in which blows air on the moving leaves.
  • a first known type of embodiment is thus constituted by a rectilinear tunnel inside which a rotating conveyor is arranged, an infrared or other heating device being additionally placed in the tunnel in association with an air ventilation system. Leaving the tunnel, the leaves are dry and are removed from the machine.
  • a second known type of embodiment consists of an endless conveyor rotating around axes placed at its ends, and which carries racks on which the printed sheets are placed.
  • This type of dryer is as long as the forced air tunnels, because only a very weak or no air flow allows only the laid leaves to stay in place.
  • Another disadvantage of this type of dryer is that the insufficiently rigid sheets touch the previous rack, which limits the possibility of use.
  • GB-A-793 216 describes a dryer without racks, in which the sheets are dried by blowing hot air flat on a table located in the upper part of the dryer.
  • the absence of racks is very annoying since the leaves can come to press against each other during their movement.
  • the insertion of the sheets into the tongs and their unloading are done in two separate consecutive operations.
  • This conveyor 1 is carried by a frame 5 in the middle of which is arranged a device 6 for blowing air of a type known per se.
  • Each series of pliers 9 is constituted, in the example shown, by a row of bent blades 12 (FIG. 3), rotatably mounted around axes or pins 13 parallel to the adjoining side of the rack 7, secured to the endless conveyor 1
  • the blades 12, preferably metallic, are bent in the example shown by forming an angle of approximately 120 degrees, the axes 13 being placed inside this angle, and supporting the blades 12 by means of ears 14 integral with the blades and in which the pins 13 are threaded.
  • the mooring device constituted by the clamps according to the invention, it is possible to ventilate with increased force, the sheets dry more quickly.
  • a lower number of racks is necessary to dry a determined quantity of sheets in a given time interval, which makes it possible to reduce the size of the machine by reducing the number of racks which it can contain.
  • the automatic opening and closing device can be produced in any other way equivalent to that described and shown in FIG. 3, for example by having fixed cams roughly similar to the heads 17 and on which the clamps would come. '' open when reaching horizontal.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Drying Of Solid Materials (AREA)
  • Supply, Installation And Extraction Of Printed Sheets Or Plates (AREA)
EP19780400265 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie Expired EP0003089B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7800305 1978-01-06
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Publications (2)

Publication Number Publication Date
EP0003089A1 EP0003089A1 (fr) 1979-07-25
EP0003089B1 true EP0003089B1 (fr) 1981-08-12

Family

ID=9203176

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19780400265 Expired EP0003089B1 (fr) 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie

Country Status (3)

Country Link
EP (1) EP0003089B1 (cg-RX-API-DMAC7.html)
DE (1) DE2860970D1 (cg-RX-API-DMAC7.html)
FR (1) FR2413974A1 (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674605B2 (en) 2006-06-07 2010-03-09 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Families Citing this family (436)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6136958A (en) 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
EP0998486B2 (en) * 1997-06-13 2012-02-01 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
ES2306480T3 (es) 1997-09-18 2008-11-01 Genentech, Inc. Polipeptido dcr3, un homologo de tnfr.
WO1999019490A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
KR100386046B1 (ko) 1997-12-03 2003-06-02 제넨테크, 인크. 폴리펩티드 및 이를 암호화하는 핵산
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
DE69939732D1 (de) 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1820859B9 (en) 1998-12-22 2009-10-28 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
BRPI0012198B8 (pt) 1999-06-25 2021-05-25 Genentech Inc anticorpos humanizados, composição e imunoconjugado
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2290081A3 (en) 1999-12-23 2012-08-01 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CA2415473A1 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CN1684708A (zh) 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE557092T1 (de) 2001-08-29 2012-05-15 Genentech Inc Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
EP1464702A4 (en) 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd METHOD FOR PROTEIN STABILIZATION
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2003072740A2 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003273218C1 (en) 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
ES2527616T3 (es) 2002-09-11 2015-01-27 Genentech, Inc. Purificación de anticuerpos anti-HER2
EP2116551A1 (en) 2002-09-11 2009-11-11 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR101118340B1 (ko) 2003-03-12 2012-04-12 제넨테크, 인크. 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도
EP1608967A4 (en) 2003-04-01 2006-08-09 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
BRPI0411276A (pt) 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
AU2004249155B2 (en) 2003-06-13 2009-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monitoring immunologic, hematologic and inflammatory diseases
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
ZA200610158B (en) 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
TWI355389B (en) 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ATE462726T1 (de) 2005-01-07 2010-04-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
KR101289537B1 (ko) 2005-02-15 2013-07-31 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
ATE526412T1 (de) 2005-04-11 2011-10-15 Ca Nat Research Council Identifizierung einer beta-1,3-n- acetylgalactosaminyltransferase (cgte) aus campylobacter jejuni lio87
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2607327A1 (en) 2005-04-29 2006-11-09 The Regents Of The University Of California Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
HRP20130400T1 (en) 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
ES2526811T3 (es) 2005-08-10 2015-01-15 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
EP2380592B1 (en) 2005-11-14 2018-03-07 Teva Pharmaceuticals International GmbH Antagonist antibody directed against calcitonin gene-related peptide
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CA2632094C (en) 2005-12-02 2015-01-27 Wayne A. Marasco Carbonic anhydrase ix (g250) antibodies and methods of use thereof
KR101538521B1 (ko) 2005-12-15 2015-07-22 제넨테크, 인크. 폴리유비퀴틴 표적화를 위한 방법 및 조성물
DK2548577T3 (en) 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
TWI596111B (zh) 2006-01-05 2017-08-21 建南德克公司 抗ｅｐｈｂ４抗體及使用該抗體之方法
US7803561B2 (en) 2006-02-06 2010-09-28 Rhode Island Hospital GPR30 estrogen receptor in breast cancers
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008060645A2 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
AU2007227195A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
KR20080110810A (ko) 2006-03-23 2008-12-19 노파르티스 아게 항-종양 세포 항원 항체 치료제
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
BRPI0710407A2 (pt) 2006-05-04 2012-04-17 Genentech Inc poliptìdeos, peixes-zebra transgênicos, modelos de sistemas, métodos de identificação de compostos, de identificação de agentes, métodos de tratamento de disfunções relativas a apoptose, método de identificação de agentes de prevenção ou redução da apoptose, composição de aumento da apoptose, composições de redução ou prevenção de apoptose, composição de apoptose, método de detecção, kits e artigo industrializado
NZ597251A (en) 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
WO2008036135A2 (en) 2006-06-01 2008-03-27 Genentech, Inc. Crystal structure of crig and c3b: crig complex
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP5248494B2 (ja) 2006-07-11 2013-07-31 ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージー タンパク質、それをコードする核酸および関連する使用方法
ES2612383T3 (es) 2006-07-19 2017-05-16 The Trustees Of The University Of Pennsylvania WSX-1/IL-27 como una diana para respuestas antiinflamatorias
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008022390A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Anti-c5ar antibodies with improved properties
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CN105061580B (zh) 2006-10-03 2020-06-05 罗格斯新泽西州立大学 多肽和药物组合物及其应用
RU2483080C2 (ru) 2006-10-27 2013-05-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применение
US8715653B2 (en) 2006-11-21 2014-05-06 The Regents Of The University Of California Modulation of Rhamm (CD168) for selective adipose tissue development
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2008350535B2 (en) 2007-05-14 2013-08-22 Novimmune S.A. Fc receptor-binding polypeptides with modified effector functions
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2689302C (en) 2007-06-08 2015-08-25 Australian Poultry Crc Pty Ltd. Clostridial toxin netb
CA3113365A1 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
AU2008308761B2 (en) 2007-10-02 2014-10-16 Genentech, Inc. NLRR-1 antagonists and uses thereof
NO2514436T3 (cg-RX-API-DMAC7.html) 2007-11-07 2018-05-19
KR20110015409A (ko) 2007-11-29 2011-02-15 제넨테크, 인크. 염증성 장 질환에 대한 유전자 발현 마커
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
WO2009079259A2 (en) 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
AU2008337100B2 (en) 2007-12-17 2013-02-28 Pfizer Limited Treatment of interstitial cystitis
JP5568478B2 (ja) 2007-12-18 2014-08-06 バイオアライアンス セー．フェー． 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
HUE050958T2 (hu) 2008-01-15 2021-01-28 Univ Leland Stanford Junior Akut mieloid leukémia õssejtek markerei
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
UA106586C2 (uk) 2008-01-31 2014-09-25 Дженентек, Інк. Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
ES2758126T3 (es) 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
ES2533480T3 (es) 2008-05-16 2015-04-10 F. Hoffmann-La Roche Ag Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CN102149728B (zh) 2008-09-10 2014-10-15 霍夫曼-拉罗奇有限公司 抑制眼部血管生成的方法
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
PL2352521T3 (pl) 2008-10-14 2021-03-08 Genentech, Inc. Warianty immunoglobuliny i ich zastosowania
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3318573A1 (en) 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Mmunoglobulin variants with altered binding to protein a
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
BRPI1012676A2 (pt) 2009-04-01 2016-04-05 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
AU2010244142B2 (en) 2009-05-05 2016-07-21 Novimmune Sa Anti-IL-17F antibodies and methods of use thereof
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CN102471381A (zh) 2009-07-07 2012-05-23 霍夫曼-拉罗奇有限公司 自身免疫性脱髓鞘疾病的诊断和治疗
JP2012533322A (ja) 2009-07-20 2012-12-27 ジェネンテック， インコーポレイテッド クローン病のための遺伝子発現マーカー
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
SI2462158T1 (en) 2009-08-06 2018-04-30 F. Hoffmann-La Roche Ag Method to improve virus removal in protein purification
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
BR112012007760A2 (pt) 2009-10-07 2015-08-25 Macrogenics Inc Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo
EP2488640B1 (en) 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
JP5814925B2 (ja) 2009-10-22 2015-11-17 ジェネンテック， インコーポレイテッド 抗ヘプシン抗体及びその使用方法
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
BR112012010153B1 (pt) 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
CA2781290A1 (en) 2009-11-20 2011-05-26 Lynn K. Gordon Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
EP4219560A3 (en) 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
TW201437228A (zh) 2010-02-23 2014-10-01 Genentech Inc 用於診斷及治療腫瘤之組合物及方法
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
AU2011225716A1 (en) 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
RS56904B1 (sr) 2010-03-30 2018-05-31 Janssen Biotech Inc Humanizovna il-25 antitela
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
BR112012028010A2 (pt) 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP3299380B1 (en) 2010-05-25 2024-08-28 F. Hoffmann-La Roche AG Methods of purifying polypeptides
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
AU2011261396B2 (en) 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
BR112013004776A2 (pt) 2010-08-27 2017-09-19 Stem Centrx Inc moduladores de proteína notum e métodos de uso
EP4226935A3 (en) 2010-08-31 2023-09-06 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
CN103476429B (zh) 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 新型调节剂及使用方法
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
JP5974012B2 (ja) 2010-10-05 2016-08-23 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
AU2011338425A1 (en) 2010-12-08 2013-05-02 Stemcentrx, Inc. Novel modulators and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
BR112013023576A2 (pt) 2011-03-15 2016-12-06 Theraclone Sciences Inc composições e métodos para a terapia e diagnóstico de influenza
MY189494A (en) 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
RS58472B2 (sr) 2011-11-02 2024-10-31 Hoffmann La Roche Hromatografija preopterećenja i eluata
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
KR20140091040A (ko) 2011-11-11 2014-07-18 리나트 뉴로사이언스 코프. Trop-2에 특이적인 항체 및 그의 용도
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
WO2013093707A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
SMT201900453T1 (it) 2012-02-06 2019-11-13 Inhibrx Inc Anticorpi anti cd47 e relativi metodi d'uso
EP3095797B1 (en) 2012-02-24 2020-05-20 AbbVie Stemcentrx LLC Anti dll3 antibodies and methods of use thereof
HUE037613T2 (hu) 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
HK1207655A1 (en) 2012-05-04 2016-02-05 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
AU2013274347B2 (en) 2012-06-11 2018-03-08 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
US20150175979A1 (en) 2012-07-23 2015-06-25 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
AU2013322710A1 (en) 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
EP2917237A1 (en) 2012-11-09 2015-09-16 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
DK2925782T3 (da) 2012-12-03 2020-04-06 Novimmune Sa Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
KR102276974B1 (ko) 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
MY174679A (en) 2013-03-13 2020-05-06 Genentech Inc Formulations with reduced oxidation
KR102317151B1 (ko) 2013-03-13 2021-10-26 제넨테크, 인크. 감소된 산화를 갖는 제제
SG11201507475UA (en) 2013-03-13 2015-10-29 Genentech Inc Antibody formulations
MX360779B (es) 2013-03-15 2018-11-16 Genentech Inc Composiciones de cultivo celular con antioxidantes y métodos para la producción de polipéptidos.
CA2901358C (en) 2013-03-15 2022-07-26 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
WO2014144763A2 (en) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
US9447193B2 (en) 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
CA2909721A1 (en) 2013-04-19 2014-10-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lone star virus
RU2015147721A (ru) 2013-05-07 2017-06-15 Ринат Нейросаенз Корпорэйшн Антитела против рецептора глюкагона и способы их использования
MX368107B (es) 2013-07-12 2019-09-18 Genentech Inc Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
US9993566B2 (en) 2013-08-28 2018-06-12 Abbvie Stemcentrx Llc SEZ6 modulators and methods of use
CN105658230B (zh) 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
EP3176185A1 (en) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
SG11201602671WA (en) 2013-11-13 2016-05-30 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
NZ720311A (en) 2013-12-02 2022-10-28 Baylor College Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
SG10201808519VA (en) 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
IL301714A (en) 2013-12-24 2023-05-01 Janssen Pharmaceutica Nv Antibodies and anti-VISTA fragments
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
ES2811274T3 (es) 2014-04-18 2021-03-11 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD99
HRP20192038T1 (hr) 2014-05-30 2020-02-07 Henlix Biotech Co., Ltd. Protutijela receptora anti-epidermalnog faktora rasta (egfr)
US20170129955A1 (en) 2014-06-17 2017-05-11 The Regents Of The University Of California Alpha-v beta-8 antibodies
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
MX384534B (es) 2014-11-05 2025-03-14 Genentech Inc Metodos de produccion de proteinas de cadena doble en bacterias.
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
EP3795168A1 (en) 2015-01-16 2021-03-24 City of Hope Cell penetrating antibodies
CN107430127B (zh) 2015-01-24 2020-08-28 中央研究院 癌症标记及其使用方法
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
CN107614523A (zh) 2015-03-30 2018-01-19 希望之城 机械互锁复合物
MY186708A (en) 2015-04-03 2021-08-11 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
JP6960856B2 (ja) 2015-04-08 2021-11-05 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化インフルエンザモノクローナル抗体およびその使用方法
SG10201912819XA (en) 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
WO2016178779A1 (en) 2015-05-01 2016-11-10 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
FI3447075T3 (fi) 2015-05-15 2023-11-07 Massachusetts Gen Hospital Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
WO2016187158A1 (en) 2015-05-15 2016-11-24 City Of Hope Chimeric antigen receptor compositions
HK1255200A1 (zh) 2015-05-29 2019-08-09 F. Hoffmann-La Roche Ag 癌症中pd-l1启动子甲基化
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
EP3310815A1 (en) 2015-06-17 2018-04-25 F. Hoffmann-La Roche AG Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
TW201718023A (zh) 2015-08-06 2017-06-01 世代好公司 細胞滲透性蛋白質－抗體結合物及使用方法
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
PT3359572T (pt) 2015-10-06 2025-01-27 H Hoffnabb La Roche Ag Método para o tratamento da esclerose múltipla
AU2016340989B2 (en) 2015-10-23 2023-09-14 Pfizer Inc. Anti-IL-2 antibodies and compositions and uses thereof
CA3007997A1 (en) 2015-12-10 2017-06-15 City Of Hope Cell penetrating cyanine-coupled antibodies
US10912776B2 (en) 2015-12-24 2021-02-09 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
ES3038408T3 (en) 2015-12-30 2025-10-13 Hoffmann La Roche Formulations with reduced degradation of polysorbate
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
JP2019506398A (ja) 2016-01-21 2019-03-07 ファイザー・インク 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
BR112018016461A2 (pt) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
US10836720B2 (en) 2016-04-01 2020-11-17 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG11201809959PA (en) 2016-05-10 2018-12-28 Genentech Inc Methods of decreasing trisulfide bonds during recombinant production of polypeptides
EP4549463A3 (en) 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies
KR102534568B1 (ko) 2016-07-22 2023-05-18 다나-파버 캔서 인스티튜트 인크. 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
CN106079858B (zh) * 2016-08-03 2017-05-17 钟晴晴 一种丝网印刷机
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
KR102617148B1 (ko) 2016-08-15 2023-12-26 제넨테크, 인크. 비이온성 계면활성제 및 폴리펩티드를 포함하는 조성물에서 비이온성 계면활성제를 정량화하기 위한 크로마토그래피 방법
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
BR112019004214A2 (pt) 2016-09-06 2019-05-28 Dana Farber Cancer Inst Inc métodos para tratar ou prevenir infecção pelo vírus zika
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
ES2977137T3 (es) 2016-09-16 2024-08-19 Shanghai Henlius Biotech Inc Anticuerpos anti-PD-1
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CA3037661A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
EP3515494A4 (en) 2016-09-26 2020-10-07 The Brigham and Women's Hospital, Inc. REGULATORS OF B-LYMPHOCYTES MEDIA IMMUNOSUPPRESSION
US10954304B2 (en) 2016-09-29 2021-03-23 The Regents Of The University Of California Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
KR20190059305A (ko) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
EP3535299A1 (en) 2016-11-04 2019-09-11 Novimmune S.A. Anti-cd19 antibodies and methods of use thereof
EP3538101B1 (en) 2016-11-14 2024-06-19 Virginia Commonwealth University Inhibitors of cancer and/or metastasis
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3565845A4 (en) 2017-01-06 2020-10-07 Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
CA3054885A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
US11726091B2 (en) 2017-04-03 2023-08-15 The Regents Of The University Of California Compositions and methods of diagnosing pancreatic cancer
JP2020512825A (ja) 2017-04-12 2020-04-30 ファイザー・インク 条件的親和性を有する抗体およびその使用の方法
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
SG11201909728XA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2018272311B2 (en) 2017-05-26 2025-06-05 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
AU2018275359C1 (en) 2017-06-02 2022-02-03 Pfizer Inc. Antibodies specific for FLT3 and their uses
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
AU2019234836A1 (en) 2018-03-13 2020-09-17 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
CA3093330A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
CN113286634A (zh) 2018-05-23 2021-08-20 辉瑞公司 对gucy2c特异性的抗体及其用途
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
KR20210040945A (ko) 2018-06-21 2021-04-14 유마니티 테라퓨틱스, 인크. 신경장애의 치료 및 예방을 위한 조성물 및 방법
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
CN120988098A (zh) 2018-06-29 2025-11-21 希望之城公司 用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
BR112021002130A2 (pt) 2018-08-08 2021-05-04 Genentech, Inc. formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
US20210393740A1 (en) 2018-09-19 2021-12-23 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
SG11202104104VA (en) 2018-11-05 2021-05-28 Genentech Inc Methods of producing two chain proteins in prokaryotic host cells
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
BR112021019571A2 (pt) 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
EP3976183A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
MX2021014953A (es) 2019-06-04 2022-01-24 Janssen Biotech Inc Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
US20220267452A1 (en) 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
JP7644087B2 (ja) 2019-07-26 2025-03-11 ヴァンダービルト ユニバーシティ エンテロウイルスｄ６８に対するヒトモノクローナル抗体
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
EP4045533B1 (en) 2020-03-26 2023-11-15 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
TW202216757A (zh) 2020-04-28 2022-05-01 美國洛克菲勒大學 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法
JP2023524125A (ja) 2020-05-05 2023-06-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病の治療方法
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
EP4178616A4 (en) 2020-07-13 2024-07-24 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY
PH12023550139A1 (en) 2020-07-17 2024-06-24 Pfizer Therapeutic antibodies and their uses
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
US20240092926A1 (en) 2021-01-20 2024-03-21 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
JP2024510588A (ja) 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
US20220315654A1 (en) 2021-03-22 2022-10-06 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022200389A1 (en) 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CN118475608A (zh) 2021-10-29 2024-08-09 詹森生物科技公司 用抗il23特异性抗体治疗克罗恩病的方法
IL312538A (en) 2021-11-05 2024-07-01 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
KR20240107176A (ko) 2021-11-15 2024-07-08 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
US20250197496A1 (en) 2022-03-18 2025-06-19 Evolvelmmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
TW202404633A (zh) 2022-04-01 2024-02-01 美商建南德克公司 用以穩定多肽之羥丙基甲基纖維素衍生物
CN118354793A (zh) 2022-04-29 2024-07-16 普瑞诺生物科技公司 用于治疗嗜酸性粒细胞驱动的疾病和病症的方法和组合物
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
CA3257687A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. METHOD FOR EVALUATING AND TREATMENT OF PSORIATIC ARTHRITIS WITH AN IL23 ANTIBODY
IL320152A (en) 2022-10-21 2025-06-01 Novimmune Sa Bispecific antibodies against PD-L1 and CD28 for immune checkpoint-dependent T cell activation
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
CN117190671B (zh) * 2023-09-13 2025-08-26 莱阳银通纸业有限公司 一种种子纸快速风干设备及方法
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
WO2025114357A1 (en) 2023-11-28 2025-06-05 Novimmune Sa Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
WO2025196691A1 (en) 2024-03-20 2025-09-25 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8030023B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. Nucleic acid encoding DR5 antibodies and uses thereof
US8409570B2 (en) 2005-02-02 2013-04-02 Genentech, Inc. Method of inducing apoptosis using anti-DR5 antibodies
US7674605B2 (en) 2006-06-07 2010-03-09 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9217048B2 (en) 2010-05-17 2015-12-22 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US9731288B2 (en) 2010-05-17 2017-08-15 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US11091551B2 (en) 2012-10-05 2021-08-17 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Also Published As

Publication number Publication date
EP0003089A1 (fr) 1979-07-25
DE2860970D1 (en) 1981-11-12
FR2413974B1 (cg-RX-API-DMAC7.html) 1982-12-03
FR2413974A1 (fr) 1979-08-03

Similar Documents

Publication Publication Date Title
EP0003089B1 (fr) Séchoir pour feuilles imprimées par sérigraphie
EP0039526B1 (fr) Dispositif de transport pour le transfert des feuilles fraîchement imprimées
CH402388A (fr) Appareil pour le façonnage d'articles à partir d'une feuille thermoplastique
EP0015314A1 (fr) Dispositif d'alimentation du papier sur une platine cylindrique tournante d'imprimante
BE1004555A3 (fr) Machine pour decouenner du lard.
EP0229554A1 (fr) Appareil pour la fixation d'agrafes de jonction sur un tapis transporteur ou similaire
EP0424290B1 (fr) Dispositif de positionnement d'un produit en forme de feuille souple
FR2541562A1 (fr) Procede de greffage automatique de la vigne et machine comportant application de ce procede
EP0086867B1 (fr) Machine à étiqueter portative
EP0220967B1 (fr) Convoyeur de récipients
EP0578551B1 (fr) Perfectionnements aux machines d'impression, notamment aux machines de sérigraphie
CH642269A5 (fr) Frein a ski.
EP0391772A1 (fr) Appareil pour la fixation d'agrafes de jonction sur un tapis transporteur ou similaire
EP0252844B1 (fr) Machine automatique pour le traitement d'un matériau en bande et notamment pour la découpe d'un tel matériau
FR2575629A1 (fr) Dispositif de montage automatique sur un substrat d'elements de circuit du type puce
FR2733491A1 (fr) Dispositif de sortie d'exemplaires imprimes d'un dispositif a roues a aubes
EP0320342B1 (fr) Plieuse
FR2552408A1 (fr) Dispositif de fixation de troncons de ruban sur des morceaux de tissu
EP0259235A1 (fr) Machine pour le prélèvement automatique de peaux ou similaires à partir d'une pile
EP0219444B1 (fr) Machine de fendage de bois à cône fileté rotatif
FR2649086A1 (fr) Distributeur de supports souples
FR2766411A1 (fr) Mecanisme d'impression thermique
CH632712A5 (en) Labelling device, particularly for bottles
FR2477504A1 (fr) Dispositif pour le pliage et le collage de bandes adhesives sur des documents plats
EP0249568A1 (fr) Manipulateur de bobines de fil pour centrifugeuses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

17P Request for examination filed
ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

REF Corresponds to:

Ref document number: 2860970

Country of ref document: DE

Date of ref document: 19811112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19811231

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: SVECIA SILKSCREEN MASKINER AB

Effective date: 19820218

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: LINDBLOM, ERIK J.

Effective date: 19820218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19831031

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19831130

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19831231

Year of fee payment: 6

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19841221

Year of fee payment: 7

Ref country code: CH

Payment date: 19841221

Year of fee payment: 7

27O Opposition rejected

Effective date: 19840722

NLR2 Nl: decision of opposition
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19851231

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19861231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19870701

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19871228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19871231

BERE Be: lapsed

Owner name: SILIUM S.F.A.R.L.

Effective date: 19871231

Owner name: DAVID BERNARD

Effective date: 19871231

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19880901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78400265.1

Effective date: 19880912